| Literature DB >> 24391878 |
Igor Loncaric1, Gabrielle L Stalder2, Kemal Mehinagic1, Renate Rosengarten1, Franz Hoelzl2, Felix Knauer2, Chris Walzer2.
Abstract
In order to test whether rooks (Corvus frugilegus) represent good indicators for the potential circulation of antibiotics in their native habitat, two populations with different migratory behavior were tested for the presence of beta-lactamase producing Enterobacteriaceae and methicillin-resistant Staphylococcus aureus (MRSA). In all, 54 and 102 samples of fresh feces of a migratory and a resident population were investigated. A total of 24 and 3 cefotaxime-resistant enterobacterial isolates were obtained from the migratory and resident population, respectively. In these isolates CTX-M-1 (n = 15), CTX-M-3 (n = 3), and CTX-M-15 (n = 3) genes were detected. TEM-1 and OXA-1 were associated with CTX-M in 3 and 2 isolates, respectively. In two E. coli isolates CMY-2 could be detected, where from one isolate displayed an overexpression of chromosomal AmpC as well. Among E. coli isolates the most common phylogenetic group was A (n = 11) and ST1683 (n = 5). In one E. coli of B2-ST131 the rfbO25b locus was detected. Three Enterobacter isolates were stably derepressed AmpC-producers. In five samples of the migratory population, PVL positive MRSA could be isolated. Two isolates were typed SCCmec IVa, spa type t127, and ST1. Three isolates carried a SCCmec type IVc, with spa type t852 and ST22. The highly significant difference of the occurrence of antibiotic resistance between the migratory population from eastern Europe compared to resident population in our study indicates that rooks may be good indicator species for the evaluation of environmental contamination with antibiotic resistant bacteria, especially due to their ecology, foraging behavior and differing migratory behavior.Entities:
Mesh:
Substances:
Year: 2013 PMID: 24391878 PMCID: PMC3877145 DOI: 10.1371/journal.pone.0084048
Source DB: PubMed Journal: PLoS One ISSN: 1932-6203 Impact factor: 3.240
Characterization of Extended-Spectrum-β-Lactamase-Producing, Plasmid-Mediated AmpC β-Lactamase-Producing and derepressed AmpC Enterobacteriaceae isolated from rooks.
| Upstream | MIC (mg/L) | ||||||||||||||||
| Isolate | Species |
| PG | ST | ISEcp1 5 | ISEcp1 UP |
| Replicon | Integron | Non-β-lactam resistance pattern | Non-β-lactam resistance genes | CTX | CAZ | MEM | CIP | GEN | FOX |
|
|
| CTX-M-1 | B1 | ST162 | 1,7 | 0,25 | 0,6 | I1-Iy(+) | − | SXT(+), TET, |
| 16 | 1 | 0,008 | 0,015 | 0,5 | n.a. |
|
|
| CTX-M-1 | A | ST744 | − | 0,25 | 0,6 | N(+) | − | CHL(+), CIP(+), SXT(+), TET(+) |
| 32 | 2 | 0,008 | 8 | 0,5 | n.a. |
|
|
| TEM-15 | A | ST23 | n.a. | n.a. | n.a. | F(+), FIB(+), I1-Iy(+) | I1a | TET(+) |
| 4 | 3 | 0,008 | 0,008 | 0,5 | n.a. |
|
|
| TEM-1, CTX-M-1 | B1 | ST58 | − | 0,25 | 0,6 | F(+), FIB(+), I1-Iy(+), N(+), P | − | CIP, SXT(+), TET |
| 16 | 1 | 0,008 | 4 | 0,5 | n.a. |
|
|
| TEM-1, CTX-M-1 | B1 | ST58 | − | 0,25 | 0,6 | F(+), FIB(+), I1-Iy(+), N(+), P | − | CIP, SXT(+), TET |
| 16 | 1 | 0,008 | 4 | 0,5 | n.a. |
|
|
| CTX-M-1 | A | ST34 | − | 0,25 | 0,6 | F(+), FIB(+), N(+) | − | CHL, GEN, SXT(+), TET |
| 64 | 0,75 | 0,008 | 0,008 | 32 | n.a. |
|
|
| CTX-M-1 | A | ST1683 | − | 0,25 | 0,6 | HI1(+) | I1b | CHL(+), GEN(+), SXT(+), TET(+) |
| 8 | 0,25 | 0,008 | 0,008 | 64 | n.a. |
|
|
| CTX-M-1 | A | ST1683 | − | 0,25 | 0,6 | F, HI1, N(+) | I1b | CHL(+), GEN, SXT(+), TET(+) |
| 16 | 1,5 | 0,008 | 0,015 | 64 | n.a. |
|
|
| CTX-M-15 | B2 | ST131 | − | 0,2 | 0,9 | F(+), FIA(+), FIB(+), Y | I1b | CIP(+), SXT(+), TOB(+) |
| >256 | 6 | 0,015 | >32 | 1 | n.a. |
|
|
| CMY-2 | E | NT | n.a. | n.a. | n.a. | NT | − | − |
| 8 | 8 | 0,015 | 0,015 | 0,5 | n.a. |
|
|
| OXA-1, CTX-M-15 | A | ST90 | − | 0,2 | 0,9 | F(+), FIA(+), FIB(+) | I1b | CIP(+), SXT(+), TET(+), TOB(+) |
| 64 | 12 | 0,008 | >32 | 1 | n.a. |
|
|
| CTX-M-1 | A | ST34 | − | 0,25 | 0,6 | F(+), FIB(+), N(+) | − | CHL, GEN, SXT(+), TET |
| 64 | 0,75 | 0,008 | 0,008 | 32 | n.a. |
|
|
| CTX-M-1 | A | ST1683 | − | 0,25 | 0,6 | HI1(+) | I1c | CHL(+), GEN(+), SXT(+), TET(+) |
| 8 | 0,38 | 0,008 | 0,008 | 32 | n.a. |
|
|
| CTX-M-1 | A | ST1683 | − | 0,25 | 0,6 | HI1 | I1b | CHL(+), GEN(+), SXT(+), TET(+) |
| 16 | 0,25 | 0,008 | 0,015 | 64 | n.a. |
|
|
| CTX-M-3 | A | ST744 | − | − | − | F(+) | − | AMK, CIP(+), CHL, FOF(+), GEN, SXT, TET(+) |
| 8 | 1 | 0,008 | 8 | 0,5 | n.a. |
|
|
| CTX-M-1 | C | ST744 | − | 0,25 | 0,6 | N(+) | − | CIP, TET |
| 16 | 2 | 0,008 | 16 | 0,5 | n.a. |
|
|
| CMY-2 | B1 | ST224 | n.a. | n.a. | n.a. | FIA, I1-Iy | − | CHL, CIP, SXT, TET |
| 8 | 24 | 0,008 | >32 | 1 | n.a. |
|
|
| CTX-M-1 | B1 | ST162 | − | 0,25 | 0,6 | NT | − | TET |
| 32 | 1 | 0,015 | 0,25 | 1 | n.a. |
|
|
| CTX-M-1 | A | ST1683 | − | 0,25 | 0,6 | HI1 | I1b | CHL(+), GEN(+), SXT(+), TET(+) |
| 16 | 0,25 | 0,008 | 0,015 | 64 | n.a. |
|
|
| OXA-1, CTX-M-15 | B2 | ST491 | − | 0,2 | 0,9 | F(+), FIA(+), FIB(+), HI1 | I1b | CIP, SXT, TOB |
| 64 | 12 | 0,008 | 0,12 | 0,5 | n.a. |
|
|
| CTX-M-1 | D | ST69 | 1,7 | 0,25 | − | F, FIB, I1-Iy(+) | − | − | − | 32 | 1 | 0,015 | 0,015 | 1 | n.a. |
|
|
| CTX-M-1 | D | ST69 | 1,7 | 0,25 | − | F, FIB, I1-Iy(+) | − | − | − | 32 | 1 | 0,015 | 0,015 | 1 | n.a. |
|
|
| TEM-1, CTX-M-3 | n.a. | n.a. | − | 0,3 | − | FIAs | − | CHL, TET | − | 32 | 1,5 | 0,008 | 0,5 | 0,5 | n.a. |
|
|
| CTX-M-3 | n.a. | n.a. | 1,7 | 0,3 | − | NT | − | − | − | 16 | 0,75 | 0,06 | 0,015 | 0,5 | n.a. |
|
|
| dAmpC | n.a. | n.a. | n.a. | n.a. | n.a. | n.a. | n.a. | − | − | >256 | 96 | 0,12 | 0,015 | 0,5 | >256 |
|
|
| dAmpC | n.a. | n.a. | n.a. | n.a. | n.a. | n.a. | n.a. | − | − | >256 | 128 | 0,12 | 0,03 | 0,5 | >256 |
|
|
| dAmpC | n.a. | n.a. | n.a. | n.a. | n.a. | n.a. | n.a. | − | − | >256 | 96 | 0,12 | 0,015 | 0,5 | >256 |
a Phylogenetic group.
b Sequence type.
c ISEcp1 5′, nexus between the 5′ region of ISEcp1 and bla CTX-M; ISEcp1 UP, nexus between ISEcp1 and bla CTX-M using forward primer for transposase gene of ISEcp1 and reverse primer for bla CTX-M; tnpA IS26, nexus between IS26 and bla CTX-M.
d in parenthesis (+) means positive after testing of transconjugants.
e I1a, class 1 integron 1.7 kb: dfr17-aadA5; I1b, class 1 integron 1.7 kb: dfr17; I1c2, class 1 integron 1.75 kb: none of cassettes could be detected.
f in parenthesis (+) means positive after testing of transconjugants. Abbreviations: AMK, amikacin; CHL, chloramphenicol; CIP, ciprofloxacin; FOF, fosfomycin; GEN, gentamicin; SXT, trimethoprim-sulfamethoxazole; TET, tetracycline; TOB, tobramycin.
g in parenthesis (+) means positive after testing of transconjugants.
h Abbreviations: CTX, cefotaxime; CAZ, ceftazidime; MEM, meropenem; CIP, ciprofloxacin; GEN, gentamicin; FOX, cefoxitin.
Characteristics of Methicillin-resistant Staphylococcus aureus (MRSA) isolated from rooks.
| MIC (mg/L) | ||||||||
| Isolate | PVL | SCC |
| ST | FOX, OX | Resistance phenotype | Resistance genotype | Exotoxin genes |
| 3mrsak | + | IVa | t127 | ST1 | 48, >256 | β-lactams, TET, CIP |
|
|
| 5mrsak | + | IVa | t127 | ST1 | 48, >256 | β-lactams, TET, CIP |
|
|
| 39mrsak | + | IVc | t852 | ST22 | 24, 32 | β-lactams, GEN, CIP |
|
|
| 41mrsak | + | IVc | t852 | ST22 | 24, 32 | β-lactams, GEN, CIP |
|
|
| 53mrsak | + | IVc | t852 | ST22 | 24, 32 | β-lactams, GEN, CIP |
|
|
a Panton-Valentine leukocidin.
b Sequence type.
c OX, oxacillin; FOX, cefoxitin.
d Antibiotics tested: penicillin, oxacillin, cefoxitin, cefovecin, cefquinome, tetracycline (TET), ciprofloxacin (CIP), gentamicin (GEN), chloramphenicol, erythromycin, clindamycin, teicoplanin, trimethoprim/sulfamethoxazole, linezolid, rifampicin and mupirocin.
Figure 1Proportion of antibiotic resistance in the two rook populations.
The percentage of antibiotic resistance rates is significantly (p<0.001) higher in the migrating (lob) population then in the resident (wul) population
Differences in the occurrence of antibiotic resistance between the migratory population (lob) and a the resistant population (wul) of rooks.
| Tested antibiotic | Migratory population (n = 54) | Resident population (n = 102) | p-value | ||
| Ampicillin | 24 | (44.44) | 3 | (2.94) | ≤0.001 |
| Piperacillin | 23 | (42.59) | 3 | (2.94) | ≤0.001 |
| Ceftazidime | 7 | (12.96) | 1 | (0.98) | ≤0.050 |
| Cefotaxime | 24 | (44.44) | 3 | (2.94) | ≤0.001 |
| Cefepim | 0 | (0.00) | 0 | (0.00) | ns |
| Doripenem | 0 | (0.00) | 0 | (0.00) | ns |
| Imipenem | 0 | (0.00) | 0 | (0.00) | ns |
| Meropenem | 0 | (0.00) | 0 | (0.00) | ns |
| Ertapenem | 0 | (0.00) | 0 | (0.00) | ns |
| Aztreonam | 6 | (11.11) | 1 | (0.98) | ≤0.050 |
| Ciprofloxacin | 8 | (14.81) | 0 | (0.00) | ns |
| Amikacin | 2 | (3.70) | 0 | (0.00) | ns |
| Gentamicin | 7 | (12.96) | 0 | (0.00) | ns |
| Tobramycin | 1 | (1.85) | 1 | (0.98) | ns |
| Tetracyclin | 18 | (33.33) | 0 | (0.00) | ns |
| Chloramphenicol | 10 | (18.52) | 0 | (0.00) | ns |
| Trimethoprim-Sulfamethoxazole | 13 | (24.07) | 1 | (0.98) | ≤0.005 |
| Fosfomycin | 1 | (1.85) | 0 | (0.00) | ns |
The number of resistant individuals per group respectively the percentage of resistant individuals per study site (in brackets) differs significantly between in the two populations for ampicillin, piperacillin, ceftazidime, cefotaxime, aztreonam and trimethoprim-sulfamethoxazole (ns indicates a non significant difference).